Analysts Offer Insights on Healthcare Companies: Intrexon (NYSE: XON) and Puma Biotechnology (NYSEArca: PBYI)

By Ryan Adsit

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intrexon (NYSE: XON) and Puma Biotechnology (NYSEArca: PBYI).

Intrexon (NYSE: XON)

In a report released today, Robert Breza from Northland Securities reiterated a Buy rating on Intrexon (NYSE: XON), with a price target of $17. The company’s shares opened today at $13.28.

According to TipRanks.com, Breza is a 4-star analyst with an average return of 6.2% and a 55.7% success rate. Breza covers the Technology sector, focusing on stocks such as Coupa Software Inc, CommVault Systems, and Brightcove Inc.

Intrexon has an analyst consensus of Moderate Buy, with a price target consensus of $17.

Puma Biotechnology (NYSEArca: PBYI)

In a report released today, Chris Shibutani from Cowen & Co. reiterated a Hold rating on Puma Biotechnology (NYSEArca: PBYI), with a price target of $70. The company’s shares opened today at $61.95.

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 23.7% and a 50.7% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Five Prime Therapeutics.

Puma Biotechnology has an analyst consensus of Moderate Buy, with a price target consensus of $100.86.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.